Late effects after high-risk neuroblastoma (LEAHRN): a multicentre, cross-sectional cohort study from the Children’s Oncology Group
Lancet Child Adolesc Health. 2025 Nov;9(11):776-786. doi: 10.1016/S2352-4642(25)00241-X. Epub 2025 Sep 25.PMID: 41016399
[DOI]



